Bergau, Leonard

[["dc.bibliographiccitation.firstpage","963"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","EP Europace"],["dc.bibliographiccitation.lastpage","970"],["dc.bibliographiccitation.volume","20"],["dc.contributor.author","Sticherling, Christian"],["dc.contributor.author","Arendacka, Barbora"],["dc.contributor.author","Svendsen, Jesper Hastrup"],["dc.contributor.author","Wijers, Sofieke"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Stockinger, Jochem"],["dc.contributor.author","Dommasch, Michael"],["dc.contributor.author","Merkely, Bela"],["dc.contributor.author","Willems, Rik"],["dc.contributor.author","Lubinski, Andrzej"],["dc.contributor.author","Scharfe, Michael"],["dc.contributor.author","Braunschweig, Frieder"],["dc.contributor.author","Svetlosak, Martin"],["dc.contributor.author","Zürn, Christine S"],["dc.contributor.author","Huikuri, Heikki"],["dc.contributor.author","Flevari, Panagiota"],["dc.contributor.author","Lund-Andersen, Caspar"],["dc.contributor.author","Schaer, Beat A"],["dc.contributor.author","Tuinenburg, Anton E"],["dc.contributor.author","Bergau, Leonard"],["dc.contributor.author","Schmidt, Georg"],["dc.contributor.author","Szeplaki, Gabor"],["dc.contributor.author","Vandenberk, Bert"],["dc.contributor.author","Kowalczyk, Emilia"],["dc.contributor.author","Eick, Christian"],["dc.contributor.author","Juntilla, Juhani"],["dc.contributor.author","Conen, David"],["dc.contributor.author","Zabel, Markus"],["dc.contributor.author","Aaboud, M. et al. (ATLAS Collaboration)"],["dc.date.accessioned","2021-11-22T14:31:38Z"],["dc.date.available","2021-11-22T14:31:38Z"],["dc.date.issued","2017"],["dc.description.abstract","Aims Therapy with an implantable cardioverter defibrillator (ICD) is established for the prevention of sudden cardiac death (SCD) in high risk patients. We aimed to determine the effectiveness of primary prevention ICD therapy by analysing registry data from 14 centres in 11 European countries compiled between 2002 and 2014, with emphasis on outcomes in women who have been underrepresented in all trials. Methods and results Retrospective data of 14 local registries of primary prevention ICD implantations between 2002 and 2014 were compiled in a central database. Predefined primary outcome measures were overall mortality and first appropriate and first inappropriate shocks. A multivariable model enforcing a common hazard ratio for sex category across the centres, but allowing for centre-specific baseline hazards and centre specific effects of other covariates, was adjusted for age, the presence of ischaemic cardiomyopathy or a CRT-D, and left ventricular ejection fraction ≤25%. Of the 5033 patients, 957 (19%) were women. During a median follow-up of 33 months (IQR 16–55 months) 129 women (13%) and 807 men (20%) died (HR 0.65; 95% CI: [0.53, 0.79], P-value < 0.0001). An appropriate ICD shock occurred in 66 women (8%) and 514 men (14%; HR 0.61; 95% CI: 0.47–0.79; P = 0.0002). Conclusion Our retrospective analysis of 14 local registries in 11 European countries demonstrates that fewer women than men undergo ICD implantation for primary prevention. After multivariate adjustment, women have a significantly lower mortality and receive fewer appropriate ICD shocks."],["dc.identifier.doi","10.1093/europace/eux176"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15529"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/93395"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.relation","info:eu-repo/grantAgreement/EC/FP7/602299/EU//EU-CERT-ICD"],["dc.relation.issn","1532-2092"],["dc.relation.issn","1099-5129"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Sex differences in outcomes of primary prevention implantable cardioverter-defibrillator therapy: combined registry data from eleven European countries"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3437"],["dc.bibliographiccitation.issue","36"],["dc.bibliographiccitation.journal","European Heart Journal"],["dc.bibliographiccitation.lastpage","3447"],["dc.bibliographiccitation.volume","41"],["dc.contributor.author","Zabel, Markus"],["dc.contributor.author","Willems, Rik"],["dc.contributor.author","Lubinski, Andrzej"],["dc.contributor.author","Bauer, Axel"],["dc.contributor.author","Brugada, Josep"],["dc.contributor.author","Conen, David"],["dc.contributor.author","Flevari, Panagiota"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Harden, Markus"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Zabel, Markus"],["dc.contributor.author","Lüthje, Lars"],["dc.contributor.author","Haarmann, Helge"],["dc.contributor.author","Bergau, Leonard"],["dc.contributor.author","Tichelbäcker, Tobias"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Zabel, Markus"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Harden, Markus"],["dc.contributor.author","Pieske, Burkert"],["dc.contributor.authorgroup","EU-CERT-ICD Study Investigators"],["dc.date.accessioned","2020-05-07T07:50:46Z"],["dc.date.accessioned","2021-10-27T13:22:10Z"],["dc.date.available","2020-05-07T07:50:46Z"],["dc.date.available","2021-10-27T13:22:10Z"],["dc.date.issued","2020"],["dc.description.abstract","Aims: The EUropean Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter-Defibrillators (EU-CERT-ICD), a prospective investigator-initiated, controlled cohort study, was conducted in 44 centres and 15 European countries. It aimed to assess current clinical effectiveness of primary prevention ICD therapy. Methods and results: We recruited 2327 patients with ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) and guideline indications for prophylactic ICD implantation. Primary endpoint was all-cause mortality. Clinical characteristics, medications, resting, and 12-lead Holter electrocardiograms (ECGs) were documented at enrolment baseline. Baseline and follow-up (FU) data from 2247 patients were analysable, 1516 patients before first ICD implantation (ICD group) and 731 patients without ICD serving as controls. Multivariable models and propensity scoring for adjustment were used to compare the two groups for mortality. During mean FU of 2.4 ± 1.1 years, 342 deaths occurred (6.3%/years annualized mortality, 5.6%/years in the ICD group vs. 9.2%/years in controls), favouring ICD treatment [unadjusted hazard ratio (HR) 0.682, 95% confidence interval (CI) 0.537–0.865, P = 0.0016]. Multivariable mortality predictors included age, left ventricular ejection fraction (LVEF), New York Heart Association class

[["dc.bibliographiccitation.firstpage","182"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","ESC Heart Failure"],["dc.bibliographiccitation.lastpage","193"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Zabel, Markus"],["dc.contributor.author","Sticherling, Christian"],["dc.contributor.author","Willems, Rik"],["dc.contributor.author","Lubinski, Andrzej"],["dc.contributor.author","Bauer, Axel"],["dc.contributor.author","Bergau, Leonard"],["dc.contributor.author","Braunschweig, Frieder"],["dc.contributor.author","Brugada, Josep"],["dc.contributor.author","Brusich, Sandro"],["dc.contributor.author","Conen, David"],["dc.contributor.author","Cygankiewicz, Iwona"],["dc.contributor.author","Flevari, Panagiota"],["dc.contributor.author","Taborsky, Milos"],["dc.contributor.author","Hansen, Jim"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Hatala, Robert"],["dc.contributor.author","Huikuri, Heikki V"],["dc.contributor.author","Iovev, Svetoslav"],["dc.contributor.author","Kääb, Stefan"],["dc.contributor.author","Kaliska, Gabriela"],["dc.contributor.author","Kasprzak, Jaroslaw D"],["dc.contributor.author","Lüthje, Lars"],["dc.contributor.author","Malik, Marek"],["dc.contributor.author","Novotny, Tomas"],["dc.contributor.author","Pavlović, Nikola"],["dc.contributor.author","Schmidt, Georg"],["dc.contributor.author","Shalganov, Tchavdar"],["dc.contributor.author","Sritharan, Rajeeva"],["dc.contributor.author","Schlögl, Simon"],["dc.contributor.author","Szavits Nossan, Janko"],["dc.contributor.author","Traykov, Vassil"],["dc.contributor.author","Tuinenburg, Anton E"],["dc.contributor.author","Velchev, Vasil"],["dc.contributor.author","Vos, Marc A"],["dc.contributor.author","Willich, Stefan N"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Svendsen, Jesper Hastrup"],["dc.contributor.author","Merkely, Béla"],["dc.date.accessioned","2019-07-09T11:50:28Z"],["dc.date.available","2019-07-09T11:50:28Z"],["dc.date.issued","2019"],["dc.description.abstract","AIMS: The clinical effectiveness of primary prevention implantable cardioverter defibrillator (ICD) therapy is under debate. The EUropean Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators (EU-CERT-ICD) aims to assess its current clinical value. METHODS AND RESULTS: The EU-CERT-ICD is a prospective investigator-initiated non-randomized, controlled, multicentre observational cohort study performed in 44 centres across 15 European Union countries. We will recruit 2250 patients with ischaemic or dilated cardiomyopathy and a guideline indication for primary prophylactic ICD implantation. This sample will include 1500 patients at their first ICD implantation and 750 patients who did not receive a primary prevention ICD despite having an indication for it (non-randomized control group). The primary endpoint is all-cause mortality; the co-primary endpoint in ICD patients is time to first appropriate shock. Secondary endpoints include sudden cardiac death, first inappropriate shock, any ICD shock, arrhythmogenic syncope, revision procedures, quality of life, and cost-effectiveness. At baseline (and prior to ICD implantation if applicable), all patients undergo 12-lead electrocardiogram (ECG) and Holter ECG analysis using multiple advanced methods for risk stratification as well as detailed documentation of clinical characteristics and laboratory values. Genetic biobanking is also organized. As of August 2018, baseline data of 2265 patients are complete. All subjects will be followed for up to 4.5 years. CONCLUSIONS: The EU-CERT-ICD study will provide a necessary update about clinical effectiveness of primary prophylactic ICD implantation. This study also aims for improved risk stratification and patient selection using clinical and ECG risk markers."],["dc.identifier.doi","10.1002/ehf2.12367"],["dc.identifier.pmid","30299600"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15947"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59780"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation","info:eu-repo/grantAgreement/EC/FP7/602299/EU//EU-CERT-ICD"],["dc.relation.issn","2055-5822"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.subject.ddc","610"],["dc.subject.mesh","Cardiomyopathy, Dilated"],["dc.subject.mesh","Death, Sudden, Cardiac"],["dc.subject.mesh","Defibrillators, Implantable"],["dc.subject.mesh","Electrocardiography"],["dc.subject.mesh","Europe"],["dc.subject.mesh","Follow-Up Studies"],["dc.subject.mesh","Humans"],["dc.subject.mesh","Patient Selection"],["dc.subject.mesh","Primary Prevention"],["dc.subject.mesh","Prospective Studies"],["dc.subject.mesh","Quality of Life"],["dc.subject.mesh","Risk Assessment"],["dc.subject.mesh","Survival Rate"],["dc.subject.mesh","Treatment Outcome"],["dc.title","Rationale and design of the EU-CERT-ICD prospective study: comparative effectiveness of prophylactic ICD implantation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1194"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","EP Europace"],["dc.bibliographiccitation.lastpage","1202"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Seegers, Joachim"],["dc.contributor.author","Conen, David"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Bergau, Leonard"],["dc.contributor.author","Dorenkamp, Marc"],["dc.contributor.author","Luethje, Lars"],["dc.contributor.author","Sohns, Christian"],["dc.contributor.author","Sossalla, Samuel"],["dc.contributor.author","Fischer, Thomas H."],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Zabel, Markus"],["dc.date.accessioned","2017-09-07T11:44:47Z"],["dc.date.available","2017-09-07T11:44:47Z"],["dc.date.issued","2016"],["dc.description.abstract","Implantable cardioverter-defibrillators (ICDs) have been shown to improve survival, although a considerable number of patients never receive therapy. Implantable cardioverter-defibrillators are routinely implanted regardless of sex. There is continuing controversy whether major outcomes differ between men and women. In this retrospective single-centre study, 1151 consecutive patients (19% women) undergoing ICD implantation between 1998 and 2010 were followed for mortality and first appropriate ICD shock over 4.9 +/- 2.7 years. Sex-related differences were investigated using multivariable Cox models adjusting for potential confounders. During follow-up, 318 patients died, a rate of 5.9% per year among men and 4.6% among women (uncorrected P = 0.08); 266 patients received a first appropriate ICD shock (6.3% per year among men vs. 3.6% among women, P = 0.002). After multivariate correction, independent predictors of all-cause mortality were age (hazard ratio, HR = 1.04 per year of age, 95% confidence interval (CI) [1.03-1.06], P < 0.001), left ventricular ejection fraction (HR = 0.98 per %, 95% CI [0.97-1.00], P = 0.025), renal function (HR = 0.99 per mL/min/1.73 m(2), 95% CI [0.99-1.00], P = 0.009), use of diuretics (HR = 1.81, 95% CI [1.29-2.54], P = 0.0023), peripheral arterial disease (HR = 2.21, 95% CI [1.62-3.00], P < 0.001), and chronic obstructive pulmonary disease (HR = 1.48, 95% CI [1.13-1.94], P = 0.029), but not sex. Female sex (HR = 0.51, 95% CI [0.33-0.81], P = 0.013), older age (HR = 0.98, 95% CI [0.97-0.99], P < 0.001), and primary prophylactic ICD indication (HR = 0.69, 95% CI [0.52-0.93], P = 0.043) were independent predictors for less appropriate shocks. Women receive 50% less appropriate shocks than men having similar mortality in this large single-centre population. These data may pertain to individually improved selection of defibrillator candidates using risk factors, e.g. sex as demonstrated in this study."],["dc.identifier.doi","10.1093/europace/euv361"],["dc.identifier.gro","3141643"],["dc.identifier.isi","000383208700014"],["dc.identifier.pmid","26622054"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13747"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/4566"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.eissn","1532-2092"],["dc.relation.issn","1099-5129"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Sex difference in appropriate shocks but not mortality during long-term follow-up in patients with implantable cardioverter-defibrillators"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e0162756"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","PLoS ONE"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Conen, David"],["dc.contributor.author","Arendacka, Barbora"],["dc.contributor.author","Roever, Christian"],["dc.contributor.author","Bergau, Leonard"],["dc.contributor.author","Munoz, Pascal"],["dc.contributor.author","Wijers, Sofieke"],["dc.contributor.author","Sticherling, Christian"],["dc.contributor.author","Zabel, Markus"],["dc.contributor.author","Friede, Tim"],["dc.date.accessioned","2018-11-07T10:08:35Z"],["dc.date.available","2018-11-07T10:08:35Z"],["dc.date.issued","2016"],["dc.description.abstract","Background Some but not all prior studies have shown that women receiving a primary prophylactic implantable cardioverter defibrillator (ICD) have a lower risk of death and appropriate shocks than men. Purpose To evaluate the effect of gender on the risk of appropriate shock, all-cause mortality and inappropriate shock in contemporary studies of patients receiving a primary prophylactic ICD. Data Source PubMed, LIVIVO, Cochrane CENTRAL between 2010 and 2016. Study Selection Studies providing at least 1 gender-specific risk estimate for the outcomes of interest. Data Extraction Abstracts were screened independently for potentially eligible studies for inclusion. Thereby each abstract was reviewed by at least two authors. Data Synthesis Out of 680 abstracts retained by our search strategy, 20 studies including 46'657 patients had gender-specific information on at least one of the relevant endpoints. Mean age across the individual studies varied between 58 and 69 years. The proportion of women enrolled ranged from 10% to 30%. Across 6 available studies, women had a significantly lower risk of first appropriate shock compared with men (pooled multivariable adjusted hazard ratio 0.62 (95% CI [0.44; 0.88]). Across 14 studies reporting'multivariable adjusted gender-specific hazard ratio estimates for all-cause mortality, women had a lower risk of death than men (pooled hazard ratio 0.75 (95% CI [0.66; 0.86]). There was no statistically significant difference for the incidence of first inappropriate shocks (3 studies, pooled hazard ratio 0.99 (95% CI [0.56; 1.73]). Limitations Individual patient data were not available for most studies. Conclusion In this large contemporary meta-analysis, women had a significantly lower risk of appropriate shocks and death than men, but a similar risk of inappropriate shocks. These data may help to select patients who benefit from primary prophylactic ICD implantation."],["dc.identifier.doi","10.1371/journal.pone.0162756"],["dc.identifier.isi","000383653100048"],["dc.identifier.pmid","27618617"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13674"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39489"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Public Library Science"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Gender Differences in Appropriate Shocks and Mortality among Patients with Primary Prophylactic Implantable Cardioverter-Defibrillators: Systematic Review and Meta-Analysis"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]